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Physiology of Implantation
When the trophectoderm, which is adjacent to the inner
cell mass of the embryonic pole, attaches to the
endometrial epithelium, an intrauterine pregnancy will
progress. Preparation for implantation occurs between
the embryo and the endometrium prior to implantation
and various factors including cytokines, which are
controlled by sex steroids produced by both the em-
bryo and endometrium, participate in the complicated
implantation cascade. Trophinin and tastin appear to
form a cell adhesion molecule complex that potentially
mediates initial attachment of the blastocyst to the
uterine epithelium at the time of implantation. These
substances are probably controlled by sex steroids in the
mouse [1]. It has been suggested that trophinin and
its related factors, such as bystin, may be involved in
implantation, particularly by facilitating adhesion. L-
selectin, which was recently discovered in trophoblasts,
is related to implantation [2]. In the cow and sheep,
interferon-o is a signal substance that trophoblasts
secrete, and it has been suggested that this is controlled
by interleukin (IL)-3 and granulocyte-macrophage col-
ony stimulating factor, which are produced by the
endometrium [3,4].
The maintenance and support of the union of two
columnar epithelial layers requires additional factors,
and the integrin family appears to play an important
role in adhesion of a cell to the external cell matrix.
Expression of integrin _v`3 is suppressed in the
endometrium of patients with unexplained infertility
who have suffered recurrent in vitro fertilization-embryo
transfer (IVF-ET) failures. Therefore, integrin _v`3
appears to be essential for connection of the embryo
to the mother [5,6]. Cytokines IL-1, IL-6, IL-11, and leu-
kemia inhibitory factor (LIF) and its receptor appear to
be involved in implantation [7–11]. IL-1 reinforces the
action of integrin. LIF mRNA concentration peaks in
human endometrium at the time of implantation, when
the blastocyst contains mRNA for the receptor [12].
Recently, we reported that Janus kinase 1 (JAK1) mRNA
is expressed in the human endometrium under the
influence of progesterone [13]. Cytokine binding induces
receptor dimerization, activating the associated JAK,
which phosphorylates the receptor. These receptor
families include substances such as gp130 and inter-
feron. JAK forms a JAK-STAT passageway by activating
a STAT protein. Thus, it plays an important role in
the transfer of a cytokine signal to the receptor, which
does not have tyrosine kinase activity. Furthermore, it
has been reported that substances, such as heparin-
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binding-epidermal growth factor (HB-EGF), calcitonin,
homeobox gene (HOXA)-10, HOXA-11, and insulin-
like growth factor binding protein-1 (IGFBP-1), are
expressed at the time of implantation as local factors
[14–17]. Although the relationship of these cytokines to
implantation appears to be quite important, the role in
humans remains unknown.
Large granular lymphocytes, which do not appear in
peripheral blood, are abundant in the endometrium.
Most of these lymphocytes are natural killer (NK) cells,
and it is thought that the function of the NK cell differs
from that of the conventional killer cell. The cytokine
network generated by these lymphocytes is thought to
influence implantation. Moreover, the Th1/Th2 cytokine
paradigm from the helper T-lymphocyte and human
leukocyte antigen (HLA) are involved in implantation. It
is thought that an extracellular matrix-related molecule
is indispensable to the invasion phenomenon that occurs
after adhesion. It is very difficult to identify all the
factors responsible for implantation and their relative
importance; however, implantation must occur via an
intricate interaction of these factors (Figure).
Concept and Categorization of Implantation
Failure
The concept of implantation failure has existed since
the 1960s, and the diagnostic definition has become
clear with IVF-ET technology. Briefly, implantation fail-
ure secondary to gross disease, such as a leiomyoma, is
common. Cases in which conception does not occur
despite the transfer of good-quality embryos (in our
hospital, three or more attempts are often made) are
considered implantation failures in a narrow sense.
The causes of implantation failure can be divided into
three types: embryonic factor, maternal factor, and
embryonic–maternal interaction factor.
Embryonic factors
The heterochromosome rate is 15% in sperm and 25% in
ova. Fragmentation of DNA reaches 5% in ova and 80%
in sperm. Ultimately, some 45% of embryos have genetic
disorders. In a recent study of embryos that reach the
blastocyst stage, chromosomal abnormalities were
found in about 40% [18]. If these heterochromatic
blastocysts are transferred, the implantation rate is low.
Conditions such as cytoplasmic denaturation of the
ovum prior to fertilization, sperm abnormalities, and
focal granulosis of the oocyte decrease the likelihood of
embryonic development.
Implantation failure may be due to a hard zona
pellucida in embryos frozen for some time.
Maternal factors
Conditions in which the endometrial cavity is distorted,
such as fibroids, endometrial polyps, endometrial
adhesions, and congenital anomalies, impact fertility.
Hysterosalpingography and hysteroscopy are effective
diagnostic modalities. Although it is often difficult to
evaluate the impact on implantation based on the grade
and state of disease, surgical correction should be taken
into consideration in patients experiencing implantation
failure.
It is generally held that not only IVF treatment but
also luteal dysfunction can result in implantation failure.
Decidualization of the endometrium by progesterone is
a phenomenon indispensable to implantation. When
using clomiphene for a long duration, particularly for
luteal dysfunction, one must consider its effect on
endometrial development. Incomplete endometrial
development is a side effect of medical treatment; thus,
the endometrium should be examined. When the
endometrial thickness is 6 mm or less, the likelihood of
pregnancy is quite low [19]. Although the underlying
mechanism for inadequate endometrial development is
currently unknown, abnormalities in secretion, such as
in steroid receptors and cytokines (growth factors),
have been implicated [20–22].
It has been reported that self-antibodies, which
respond abnormally in autoimmunity such as that found
in systemic lupus erythematosus, prevent implantation.
Assisted reproductive technology (ART) treatment, low-
dose aspirin, and prednisone are effective in promoting
implantation in such cases. Although low-dose aspirin
affects neither endometrial thickness nor uterine artery
resistance, it improves the endometrial environment. It
has been reported that aspirin administration results in
higher pregnancy rates and better endometrial patterns
in patients with a thin endometrium [23].
Figure. Pre-attachment and invasion.
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Embryonic–maternal interaction factors
Some abnormalities in embryonic–maternal interaction,
such as functional disorders and signal transfer obstacles,
may lead to implantation failure. However, the aspects
of this have not yet been clarified. Basic research is
needed to develop effective treatment for this type of
implantation failure.
Improvement of Pregnancy Rates in ART
Preimplantation diagnosis
In embryo biopsy, a portion of the embryo is extracted
and subjected to genetic analysis. Although this has
been used clinically in Western countries for about 15
years [24], many ethical problems are unresolved in
Japan.
Blastocyst transfer
From fertilization until the eight-cell stage, the fertilized
ova are cultured in a solution with a glutamine base and
ethylenediamine tetraacetic acid (EDTA); subsequent-
ly, glucose is added as an energy source. Because of re-
finements in sequential culture media, embryos readily
develop to the blastocyst stage, which is the optimal
point for embryo transfer because the hetero-
chromosome rate is low [25]. An implantation rate of
35% with day 3 embryos has been reported; the rate
rose to 55% with day 5 embryos [26–28]. However,
these investigators reported that the frequency of
monozygotic twinning was high with blastocyst
transfer. The frequency of monozygotic twinning is
about 0.4% in natural pregnancies; however, it has
been reported that the rate of monozygotic twinning
with conventional day 3 transfer is about 2%, and
blastocyst transfer has a rate of about 5%. This
phenomenon should be fully explained to the patient
prior to treatment [29].
Frozen embryo transfer
This technique is indispensable to ART; it avoids multiple
gestations as well as ovarian hyperstimulation syndrome
by using surplus embryos that have been preserved. Its
applications and adaptations have expanded. Although
concern exists in regard to deterioration of the embryo,
it has been reported that the birth defect rate is no
higher than in natural pregnancies.
The zona pellucida hardens as a result of freezing,
but this problem has been resolved using assisted
hatching (AH). For implantation to occur, the embryo
and the endometrium must be synchronized. Often,
synchronization is not present during the stimulus cy-
cle; thus, frozen embryos can be transferred during a
subsequent, synchronized cycle. In cases of a thin en-
dometrium, the lining can be enhanced in subsequent
cycles prior to transfer.
Two-step transfer
The rationale of this transfer method is based on the
fact that the endometrium is optimal for implantation
when the embryo is transiting the oviduct [30,31]. The
implantation rate increases from 30% with transfer of
cleavage-stage embryos on day 2 to 59.7% with trans-
fer of blastocyst-stage embryos on day 5, which is
statistically significant [32].
Other factors than the embryo may influence the
endometrial immune environment for implantation.
One problem with the two-step transfer method is an
increased risk of multiple gestations. Furthermore, this
technique cannot be used when a small number of ova
are harvested. Further investigation of this technique,
comparing two-step transfer with blastocyst transfer,
is necessary.
Assisted hatching
The zona pellucida, which surrounds the ovum, is
influenced by protease; it becomes soft and thin during
the process of implantation (hatching). It is thought
that thickening and hardening of the zona pellucida
result in a decreased implantation rate. Some or all of
the zona pellucida is removed either chemically or
mechanically in AH, which was adopted for ART after
being reported by Cohen in 1990 and has become
commonplace [33]. Mechanical AH entails boring a
small hole in the zona pellucida using a laser and a
micromanipulator (partial zona dissection). Chemical
AH uses an acid enzyme solution and is carried out to
three levels: partial zona thinning, circumferential zona
thinning, and zona removal.
The rate of monozygotic twins and ectopic preg-
nancies with AH is unusually high, according to re-
cent reports [34–36]; thus, informed consent is indi-
cated. Furthermore, while success with AH has been
reported for elderly patients, others question its value
for these women [37,38]. Further modification of AH is
required.
Prospective View
When studying implantation, the subject of ectopic
implantation arises; this situation strongly supports
an embryonic factor resulting in implantation. Global
genetic analysis has further clarified the implantation
mechanism. The protein-array procedure, which analyzes
many proteins simultaneously, develops a microarray
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that has potential clinical usefulness. If the genes and
proteins involved in implantation failure are identified,
detection and correction of implantation defects can be
attained.
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